Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cipla
Johnson and Johnson
Argus Health
Teva
Colorcon
Boehringer Ingelheim
Julphar
Medtronic
Merck

Generated: October 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018164

« Back to Dashboard
NDA 018164 describes ANAPROX DS, which is a drug marketed by Atnahs Pharma Us and is included in one NDA. It is available from three suppliers. Additional details are available on the ANAPROX DS profile page.

The generic ingredient in ANAPROX DS is naproxen sodium. There are forty-two drug master file entries for this compound. One hundred and sixty-two suppliers are listed for this compound. Additional details are available on the naproxen sodium profile page.

Summary for NDA: 018164

Tradename:
2
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 018164

Suppliers and Packaging for NDA: 018164

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ANAPROX
naproxen sodium
TABLET;ORAL 018164 NDA Genentech, Inc. 0004-6203 0004-6203-01 100 TABLET in 1 BOTTLE, PLASTIC (0004-6203-01)
ANAPROX
naproxen sodium
TABLET;ORAL 018164 NDA Cameron Pharmaceuticals, LLC 42494-400 42494-400-01 100 TABLET in 1 BOTTLE, PLASTIC (42494-400-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 250MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 500MG BASE
Approval Date:Sep 30, 1987TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 018164

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Atnahs Pharma Us
ANAPROX DS
naproxen sodium
TABLET;ORAL018164-003Sep 30, 1987► Subscribe► Subscribe
Atnahs Pharma Us
ANAPROX
naproxen sodium
TABLET;ORAL018164-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Atnahs Pharma Us
ANAPROX
naproxen sodium
TABLET;ORAL018164-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Atnahs Pharma Us
ANAPROX DS
naproxen sodium
TABLET;ORAL018164-003Sep 30, 1987► Subscribe► Subscribe
Atnahs Pharma Us
ANAPROX DS
naproxen sodium
TABLET;ORAL018164-003Sep 30, 1987► Subscribe► Subscribe
Atnahs Pharma Us
ANAPROX
naproxen sodium
TABLET;ORAL018164-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Healthtrust
AstraZeneca
Farmers Insurance
US Department of Justice
Cerilliant
Boehringer Ingelheim
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot